The Worldwide Male Hypogonadism Industry is Expected to Reach $5 Billion by 2030

2022-10-24
PRNewswire
DUBLIN, Oct. 24, 2022 /PRNewswire/ -- The "Male Hypogonadism Market By Drug Delivery, By Therapy, By Type: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to
ResearchAndMarkets.com's offering.
The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030.
Hypogonadism is characterized as lack of testosterone level or lack of spermatozoa production, or both. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). Both can be inherited or acquired, due to ageing, hormonal disorders or medicines. In addition, various congenital enzyme abnormalities result in various degrees of androgen resistance in target organs. Hormone levels corroborate the diagnosis. The treatment for gonadotropin-releasing hormone, gonadotropin, or testosterone replacement differs depending on the aetiology.
The factors that drive the global male hypogonadism market are increase in cases of hypogonadism, surge in awareness of hypogonadism, and rise in number of treatment options. In addition, hypogonadism is prevalent in the geriatric population as well as in patients with diabetes and obesity.
As a result, increase in population and rise in the incidence and prevalence of chronic disorders, such as diabetes and obesity drive the growth of the market. According to clinical research, testosterone levels in males aged 60-80 years are 20 percent and 80 percent lower, respectively, than testosterone levels in young men. Hypogonadism is most common in men aged above 60. In countries like Japan, China, and the U.S. there is surge in demand for male hypogonadism treatments, owing to increase in geriatric population and surge in infertility rates.
The male hypogonadism market is segmented on the basis of therapy, drug delivery, type, and region. Depending on therapy, it is divided into testosterone replacement therapy and gonadotropin & gonadotropin-releasing hormones therapy. The gonadotropin-releasing hormones therapy segment is segmented into luteinizing hormone (LH), follicle-stimulating hormone (FSH), human chorionic gonadotropin (HCG), and gonadotropin-releasing hormone (GNRH).
According to drug delivery, it is fragmented into topical gels, injectable, transdermal patches, and others. As per the type, it is classified into Klinefelter's syndrome, Kallmann syndrome, pituitary disorders, and others. Region wise, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the male hypogonadism market analysis from 2020 to 2030 to identify the prevailing male hypogonadism market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the male hypogonadism market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global male hypogonadism market trends, key players, market segments, application areas, and market growth strategies.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter's five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19COVID-19 Impact Analysis on the market
CHAPTER 4: MALE HYPOGONADISM MARKET, BY DRUG DELIVERY
4.1 Overview
4.1.1 Market size and forecast
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Injectables
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: MALE HYPOGONADISM MARKET, BY THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Testosterone Replacement Therapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Gonadotropin and Gonadotropin Releasing Hormone Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: MALE HYPOGONADISM MARKET, BY TYPE
6.1 Overview
6.1.1 Market size and forecast
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Others
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
CHAPTER 7: MALE HYPOGONADISM MARKET, BY REGION
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Ferring
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
For more information about this report visit https://www.researchandmarkets.com/r/7cmwd4
Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。